1 month ago
8
Soumya Eswaran
Thu, July 30, 2026 astatine 8:15 AM CDT 3 min read
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 capitalist missive for "Meridian Small Cap Growth Fund". A transcript of the missive tin beryllium downloaded here. The U.S. marketplace saw a beardown rally successful the 2nd quarter, fueled by easing geopolitical tensions, falling lipid prices, and robust firm earnings. Growth stocks, particularly successful exertion and healthcare, led the charge, supported by AI-related investments from hyperscalers that added momentum. Meanwhile, accepted harmless havens similar golden declined. In this context, the Meridian Small Cap Growth Fund (the "Fund") achieved a 21.54% instrumentality for the 4th ending June 30, 2026. This lagged down its benchmark, the Russell 2000 Growth Index, which gained 25.71%, owed to origin and benignant headwinds—as high-beta and momentum stocks soared, its lower-volatility, quality-focused holdings underperformed. The Fund continues to prioritize prime businesses, hazard management, and downside protection, with portfolio adjustments driven by strategical allocation alternatively than weaknesses successful idiosyncratic holdings. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.
In its Q2 2026 capitalist letter, Meridian Small Cap Growth Fund highlighted Tandem Diabetes Care, Inc. (NASDAQ:TNDM). Headquartered successful San Diego, California, Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is simply a aesculapian instrumentality institution that offers exertion solutions for radical surviving with diabetes. On July 29, 2026, Tandem Diabetes Care, Inc. (NASDAQ:TNDM) closed astatine $18.59 per share, reflecting a marketplace capitalization of $1.27 billion. Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted a one-month instrumentality of 21.34%, portion its shares gained 19.32% implicit the past 52 weeks.
Meridian Small Cap Growth Fund stated the pursuing regarding Tandem Diabetes Care, Inc. (NASDAQ:TNDM) successful its Q2 2026 capitalist update:
"Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is simply a aesculapian instrumentality institution focused connected insulin delivery, champion known for its t:slim X2 and Mobi automated insulin pumps. We ain it for its differentiated pump technology, increasing installed base, and the recurring proviso gross that expands with its idiosyncratic base. Shares declined during the 4th arsenic the company's modulation to a pharmacy-based, pay-as-you-go reimbursement exemplary clouded near-term gross visibility, and second-quarter guidance came successful beneath expectations adjacent arsenic the underlying 4th was broadly successful line. Heightened attraction to a caller competing patch-pump entrant added to the caution, and the name's lower-beta illustration lagged successful a marketplace that favored higher-beta and non-earning stocks; we proceed to judge the reimbursement modulation is simply a semipermanent positive."
English (CA) · 
English (US) · 
Spanish (MX) ·